Literature DB >> 35288633

Deep brain stimulation of the "medial forebrain bundle": sustained efficacy of antidepressant effect over years.

Albert J Fenoy1,2, Paul E Schulz3, Marsal Sanches4, Sudhakar Selvaraj4, Christina L Burrows3, Bashar Asir4, Christopher R Conner5, Joao Quevedo4, Jair C Soares4.   

Abstract

Deep brain stimulation (DBS) to the superolateral branch of the medial forebrain bundle (MFB) has emerged as a quite efficacious therapy for treatment resistant depression (TRD), leading to rapid antidepressant effects. In this study, we complete our assessment of our first 10 enrolled patients throughout one year post-implantation, showing sustained antidepressant effect up to 5 years. The primary outcome measure was a 50% reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) score, which was interpreted as a response. Deterministic fiber tracking was used to individually map the target area. An insertional effect was seen during the 4-week sham stimulation phase (29% mean MADRS reduction, p = 0.02). However, after 2 weeks of initiating stimulation, five patients met response criteria (47% mean MADRS reduction, p < 0.001). One patient withdrew from study participation at 6 weeks. Twelve weeks after initiating stimulation, six of nine remaining patients had a >50% decrease in MADRS scores relative to baseline (52% mean MADRS reduction, p = 0.001); these same six patients continued to meet response criteria at 52 weeks (63% overall mean MADRS reduction, p < 0.001). Four of five patients who achieved the 5-year time point analysis continued to be responders (81% mean MADRS reduction, p < 0.001). Evaluation of modulated fiber tracts reveals significant common prefrontal/orbitofrontal connectivity to the target region in all responders. Key points learned from this study that we can incorporate in future protocols to better elucidate the effect of this therapy are a longer blinded sham stimulation phase and use of scheduled discontinuation concomitant with functional imaging.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35288633     DOI: 10.1038/s41380-022-01504-y

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   13.437


  46 in total

Review 1.  Clinical practice. Essential tremor.

Authors:  E D Louis
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  A Randomized Sham-Controlled Trial of Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Chronic Treatment-Resistant Depression.

Authors:  Darin D Dougherty; Ali R Rezai; Linda L Carpenter; Robert H Howland; Mahendra T Bhati; John P O'Reardon; Emad N Eskandar; Gordon H Baltuch; Andre D Machado; Douglas Kondziolka; Cristina Cusin; Karleyton C Evans; Lawrence H Price; Karen Jacobs; Mayur Pandya; Timothey Denko; Audrey R Tyrka; Tim Brelje; Thilo Deckersbach; Cynthia Kubu; Donald A Malone
Journal:  Biol Psychiatry       Date:  2014-12-13       Impact factor: 13.382

Review 3.  Essential tremor.

Authors:  Elan D Louis
Journal:  Lancet Neurol       Date:  2005-02       Impact factor: 44.182

4.  Deep brain stimulation for treatment-resistant depression.

Authors:  Helen S Mayberg; Andres M Lozano; Valerie Voon; Heather E McNeely; David Seminowicz; Clement Hamani; Jason M Schwalb; Sidney H Kennedy
Journal:  Neuron       Date:  2005-03-03       Impact factor: 17.173

5.  Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression.

Authors:  Paul E Holtzheimer; Mary E Kelley; Robert E Gross; Megan M Filkowski; Steven J Garlow; Andrea Barrocas; Dylan Wint; Margaret C Craighead; Julie Kozarsky; Ronald Chismar; Jared L Moreines; Klaus Mewes; Patricio Riva Posse; David A Gutman; Helen S Mayberg
Journal:  Arch Gen Psychiatry       Date:  2012-01-02

Review 6.  Essential tremor--neurodegenerative or nondegenerative disease towards a working definition of ET.

Authors:  Günther Deuschl; Rodger Elble
Journal:  Mov Disord       Date:  2009-10-30       Impact factor: 10.338

7.  Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression.

Authors:  Andres M Lozano; Helen S Mayberg; Peter Giacobbe; Clement Hamani; R Cameron Craddock; Sydney H Kennedy
Journal:  Biol Psychiatry       Date:  2008-07-18       Impact factor: 13.382

8.  Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression.

Authors:  Bettina H Bewernick; René Hurlemann; Andreas Matusch; Sarah Kayser; Christiane Grubert; Barbara Hadrysiewicz; Nikolai Axmacher; Matthias Lemke; Deirdre Cooper-Mahkorn; Michael X Cohen; Holger Brockmann; Doris Lenartz; Volker Sturm; Thomas E Schlaepfer
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

9.  Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial.

Authors:  Paul E Holtzheimer; Mustafa M Husain; Sarah H Lisanby; Stephan F Taylor; Louis A Whitworth; Shawn McClintock; Konstantin V Slavin; Joshua Berman; Guy M McKhann; Parag G Patil; Barry R Rittberg; Aviva Abosch; Ananda K Pandurangi; Kathryn L Holloway; Raymond W Lam; Christopher R Honey; Joseph S Neimat; Jaimie M Henderson; Charles DeBattista; Anthony J Rothschild; Julie G Pilitsis; Randall T Espinoza; Georgios Petrides; Alon Y Mogilner; Keith Matthews; DeLea Peichel; Robert E Gross; Clement Hamani; Andres M Lozano; Helen S Mayberg
Journal:  Lancet Psychiatry       Date:  2017-10-04       Impact factor: 27.083

10.  Deep Brain Stimulation of the Ventral Anterior Limb of the Internal Capsule for Treatment-Resistant Depression: A Randomized Clinical Trial.

Authors:  Isidoor O Bergfeld; Mariska Mantione; Mechteld L C Hoogendoorn; Henricus G Ruhé; Peter Notten; Jan van Laarhoven; Ieke Visser; Martijn Figee; Bart P de Kwaasteniet; Ferdinand Horst; Aart H Schene; Pepijn van den Munckhof; Guus Beute; Rick Schuurman; Damiaan Denys
Journal:  JAMA Psychiatry       Date:  2016-05-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.